OTCPK:AMEU.F

Stock Analysis Report

Executive Summary

Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Admedus has significant price volatility in the past 3 months.
  • Admedus is not covered by any analysts.

Share Price & News

How has Admedus's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:AMEU.F

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

n/a

OTCPK:AMEU.F

9.9%

US Medical Equipment

1.6%

US Market

No trading data on AMEU.F.

No trading data on AMEU.F.


Share holder returns

AMEU.FIndustryMarket
7 Day0%0.5%-0.02%
30 Day33.2%0.09%2.7%
90 Day-39.3%2.0%1.4%
1 Yearn/a10.8%9.9%3.8%1.6%
3 Year-61.6%-61.6%69.0%63.9%45.2%35.8%
5 Year-28.0%-28.0%136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Admedus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Admedus undervalued based on future cash flows and its price relative to the stock market?

3.56x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Admedus to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Admedus to establish if it is available at substantial discount.


Price Based on Earnings

Admedus is loss making, we can't compare its value to the US Medical Equipment industry average.

Admedus is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Admedus, we can't assess if its growth is good value.


Price Based on Value of Assets

Admedus is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Admedus expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Admedus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of AMEU.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Admedus's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Admedus performed over the past 5 years?

-6.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Admedus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Admedus's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Admedus's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Admedus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Admedus has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Admedus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Admedus's financial position?


Financial Position Analysis

Admedus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Admedus's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Admedus's level of debt (9.9%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Admedus's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 13.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Admedus has less than a year of cash runway based on current free cash flow.

Admedus has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.6% each year.


Next Steps

Dividend

What is Admedus's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Admedus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Admedus's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Admedus has not reported any payouts.

Unable to verify if Admedus's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Admedus has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Admedus's salary, the management and board of directors tenure and is there insider trading?

0.9yrs

Average management tenure


CEO

Wayne Paterson (52yo)

2.5yrs

Tenure

AU$1,232,760

Compensation

Mr. Wayne G. Paterson is the Founder and Chief Executive Officer of ProCom Rx since June 2013. Mr. Paterson has been Chief Executive Officer of Admedus Limited since March 15, 2017 and has been its Managin ...


CEO Compensation Analysis

Wayne's remuneration is higher than average for companies of similar size in United States of America.

Wayne's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

0.9yrs

Average Tenure

The average tenure for the Admedus management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.9yrs

Average Tenure

The average tenure for the Admedus board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Ian Frazer

    Executive

    • Tenure: 0yrs
  • Wayne Paterson (52yo)

    CEO, President

    • Tenure: 2.5yrs
    • Compensation: AU$1.23m
  • Danny Zanardo

    Commercial Director of International

    • Tenure: 0yrs
  • Chris Olig

    Business Development and Portfolio Planning Director

    • Tenure: 3yrs
  • David Denis

    Chief Operating Officer

    • Tenure: 2.2yrs
    • Compensation: AU$776.69k
  • Steve Denaro

    Non-Executive Director & Company Secretary

    • Tenure: 0.9yrs
    • Compensation: AU$26.67k
  • Matthew McDonnell

    Interim Chief Financial Officer

    • Tenure: 0.8yrs
    • Compensation: AU$330.71k
  • Kiran Bhirangi

    Chief Medical Officer

    • Tenure: 0.8yrs
    • Compensation: AU$449.16k
  • Angela Frisinger

    Global Head of Human Resources

    • Tenure: 0.3yrs
  • Martha Engel

    General Council

    • Tenure: 0.5yrs

Board Members

  • John Seaberg (67yo)

    Chairman of the Board

    • Tenure: 2.5yrs
    • Compensation: AU$154.42k
  • Wayne Paterson (52yo)

    CEO, President

    • Tenure: 2.5yrs
    • Compensation: AU$1.23m
  • Wenyi Gu

    Non-Executive Director

    • Tenure: 0.9yrs
    • Compensation: AU$18.33k
  • Steve Denaro

    Non-Executive Director & Company Secretary

    • Tenure: 0.9yrs
    • Compensation: AU$26.67k
  • Yanheng Wu

    Non-Executive Director

    • Tenure: 0.8yrs

Company Information

Admedus Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Admedus Limited
  • Ticker: AMEU.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$35.445m
  • Listing Market Cap: AU$24.252m
  • Shares outstanding: 590.74m
  • Website: https://www.admedus.com

Location

  • Admedus Limited
  • Toowong Tower
  • Suite 302
  • Toowong
  • Queensland
  • 4066
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AHZASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJun 2011
AMEU.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2011
AHZCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJun 2011
DDFDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2011

Biography

Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue prod ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 00:05
End of Day Share Price2019/09/06 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.